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Abstract
Introduction: Approximately 30 % of juvenile idiopathic arthritis (JIA) patients fail to respond to anti-TNF treatment.
When clinical remission is induced, some patients relapse after treatment has been stopped. We tested the predictive
value of MRP8/14 serum levels to identify responders to treatment and relapse after discontinuation of therapy.
Methods: Samples from 88 non-systemic JIA patients who started and 26 patients who discontinued TNF-blockers
were analyzed. MRP8/14 serum levels were measured by in-house MRP8/14 ELISA and by Bühlmann Calprotectin ELISA
at start of anti-TNF treatment, within 6 months after start and at discontinuation of etanercept in clinical remission.
Patients were categorized into responders (ACRpedi≥ 50 and/or inactive disease) and non-responders (ACRpedi < 50)
within six months after start, response was evaluated by change in JADAS-10. Disease activity was assessed within six
months after discontinuation.
Results: Baseline MRP8/14 levels were higher in responders (median MRP8/14 of 1466 ng/ml (IQR 1045–3170))
compared to non-responders (median MRP8/14 of 812 (IQR 570–1178), p < 0.001). Levels decreased after start of
treatment only in responders (p < 0.001). Change in JADAS-10 was correlated with baseline MRP8/14 levels (Spearman’s
rho 0.361, p = 0.001). Patients who flared within 6 months after treatment discontinuation had higher MRP8/14 levels
(p = 0.031, median 1025 ng/ml (IQR 588–1288)) compared to patients with stable remission (505 ng/ml (IQR 346–778)).
Results were confirmed by Bühlmann ELISA with high reproducibility but different overall levels.
Conclusion: High levels of baseline MRP8/14 are associated with good response to anti-TNF treatment, whereas
elevated MRP8/14 levels at discontinuation of etanercept are associated with higher chance to flare.
Introduction
Addition of biologic agents for treatment of juvenile
idiopathic arthritis (JIA) has brought the treatment goal
of inactive disease into reach even for JIA patients not
responding to conventional disease-modifying anti-
rheumatic drugs (DMARDs). However, 30–40 % of patients
treated with biologic agents do not achieve this treatment
goal for unknown reasons [1–3]. Several clinical parameters
have been found to be associated with response to eta-
nercept, a TNF-alpha inhibitor and the first biologic agent
to be approved for the treatment of JIA [4, 5]. These in-
clude patient characteristics, such as age and gender, and
disease characteristics, such as number of active joints, ex-
tent of disability and disease duration. However, as none
of these factors are perfectly able to distinguish between
responders and non-responders, these clinical charac-
teristics in themselves are not sufficient to guide treatment
decisions. A more tailored approach to drug choice, based
upon use of validated biomarkers in combination with
clinical parameters, could facilitate early remission in-
duction for more children. Measurement of serum in-
flammatory proteins before starting treatment with a
biologic agent may be valuable to separate children with a
high chance of good response from poor responders or
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non-responders. In addition, biomarkers could be of help
in identifying patients in clinical remission who can suc-
cessfully discontinue treatment.
The myeloid related protein (MRP) complex 8/14
(S100A8/9, also known as calprotectin) is released from
activated monocytes and phagocytes. MRP8/14 is a ligand
to toll-like receptor 4 (TLR-4), has a pro-inflammatory ef-
fect on phagocytes and endothelial cells [6] and is an im-
portant factor in mediating osteoclastic bone destruction
in experimental arthritis [7]. MRP8/14 serum levels cor-
relate with disease activity in JIA patients [8], can be used
to identify subclinical disease activity, and are associated
with flares in JIA patients in clinical remission on metho-
trexate (MTX) [9, 10]. In addition, this biomarker corre-
lates closely to response to treatment in patients with
systemic JIA [11] and is able to predict good response to
MTX in a subset of patients with non-systemic JIA [12].
Whether MRP8/14 is also associated with response to
TNF-alpha inhibitors in patients with non-systemic JIA,
or can predict flares after discontinuation of etanercept
after successful treatment when clinical remission is
achieved, is unknown. Therefore, in the present study we
prospectively evaluated the relationship between the clin-
ical course of JIA after anti-TNF treatment and after dis-
continuation of etanercept and serum levels of MRP8/14.
Methods
Study population
Serum samples were included from patients with non-
systemic JIA who were biologic-agent-naïve, starting ei-
ther etanercept or adalimumab, and included in the Dutch
Arthritis and Biologicals in Children (ABC) Register
(n = 68), German Registry for Biologics in Pediatric
Rheumatology (BIKER) (n = 12) or Childhood Arthritis
Response to Medication Study (CHARMS) from the
United Kingdom (n = 8). Additionally samples from 26
patients at discontinuation of etanercept in remission
were collected ((ABC register (n = 8), BIKER register
(n = 18)). The list of participating hospitals can be found
in the Acknowledgements section. Patients fulfilled the
International League of Associations for Rheumatology
criteria for JIA [13]. Patients diagnosed with systemic JIA
have been described elsewhere [11].
The ABC register is a multicenter prospective observa-
tional study that aimed to include all JIA patients in the
Netherlands who initiated biologic agents. The study
protocol was approved by the Medical Ethics Committee
at Erasmus MC Rotterdam and by all participating hos-
pitals [3]. The German BIKER register was founded with
the same objective, after approval by the ethics committee
of the University Halle [1]. The CHARMS study (approved
by the Institute of Child Health/Great Ormond Street
NHS Trust Ethics Committee) included JIA patients
at the start of treatment with new disease-modifying
medication for active arthritis [12]. For all studies,
written informed consent was obtained. In all three stud-
ies patient and disease characteristics were recorded at the
start of biologic treatment. Changes in disease activity,
medication use and adverse events were followed pro-
spectively. These included the JIA core set variables:
physician’s global assessment (PGA) of disease activity
on a visual analog scale (VAS) (range 0–10 cm, 0 best
score), childhood health assessment questionnaire (CHAQ)
(range 0–3, 0 best score), the global assessment of well-
being VAS completed by patients/parents (range 0–10 cm,
0 best score, number of joints with active arthritis and
joints with limited motion and erythrocyte sedimentation
rate (ESR)). Additionally pain was assessed using a VAS
completed by parents/patients. Anti-TNF treatment was
prescribed according to standard dosing for pediatric JIA
patients.
Response to treatment, inactive disease and flare
The effect of treatment was assessed using the ACR
pediatric response criteria [14]. A modified definition for
inactive disease was used and defined as no active arthritis,
no systemic features, no uveitis, normal ESR (≤20 mm/h),
and physician’s global assessment of disease activity indi-
cating no disease activity (defined as a score ≤1.0 cm) [15].
The modified definition includes PGA with an increased
threshold, because in daily practice we experience a fear
of physicians to set the disease activity at zero, as while
the disease is inactive, patients are not cured and still
require medication. Patients were divided into responders
who achieved at least an ACRpedi50 response (subdivided
into ACRpedi50, ACRpedi70 or inactive disease) and
non-responders (patients with no response or an
ACRpedi30 response) within 6 months after start of
treatment (median time of follow-up evaluation was
3.2 months (IQR 2.6 − 5.0). Additionally, response to
treatment was evaluated using change on the continuous
juvenile arthritis disease activity score (JADAS)-10 score,
a composite score based on four of the disease activity var-
iables (PGA, VAS wellbeing (parent/patient), active joint
count and ESR). JADAS-10 was assessed at the start and
within 6 months after the start of treatment [16].
Patients who discontinued treatment were all in remis-
sion on medication (defined as a period of ≥6 months of
continuous inactive disease, using the modified Wallace
criteria as described above) [17]. For evaluation of the
association between MRP 8/14 levels at discontinuation
and flaring after discontinuation, we defined flare as hav-
ing at least three of the following: a physician or patient
VAS ≥20 mm, ≥1 active joints, any worsening on the
CHAQ and ≥30 % worsening of ESR and limited joints
[18, 19]. Patients who had flares no longer fulfilled the
modified Wallace criteria. Patients who did not have
flares still met these criteria.
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Determination of MRP8/14 serum levels
Serum levels of MRP8/14 complexes were determined
by ELISA. For comparison with earlier studies, internal
control sera were used as a reference in all ELISA stud-
ies. MRP8/14 serum levels in healthy pediatric controls
have been repeatedly measured with our in-house ELISA
with results in the range of 310 ± 40 ng/ml [11]. Add-
itionally, MRP8/14 levels were also measured using the
commercially available Bühlmann MRP8/14 Calprotectin
ELISA (Bühlmann Laboratories Schönenbuch, Zwitserland)
to investigate inter-assay variation. The readers of the assay
were blinded to diagnosis and disease activity. Treating
physicians were blinded to the MRP8/14 serum levels.
Statistical analysis
Patients starting etanercept and adalimumab were ana-
lyzed together, as the number of patients treated with
adalimumab was too small to analyze separately. Although
the two drugs are different in structure, both drugs are
TNF-alpha blockers, and we therefore expect the effect on
MRP8/14 levels in responders/non-responders to be com-
parable. Descriptive statistics are presented as absolute
frequencies, as median values and IQR, or as mean and
SD, as appropriate. The chi-square test was used to com-
pare categorical characteristics of responders with those of
non-responders. The Mann–Whitney U test was used for
comparison of continuous variables. Correlations between
serum level of MRP8/14 and clinical variables were
assessed using Spearman’s correlation coefficient. Correl-
ation between the in-house ELISA and the Bühlmann
ELISA was assessed using Pearson’s correlation coefficient.
The Wilcoxon signed rank test was used to analyze differ-
ences in MRP8/14 levels at paired time points. Receiver
operator characteristic (ROC) analyses were performed to
determine optimal cutoff levels separately for both assays
to predict response to treatment and flare within 6 months
after treatment discontinuation. Cutoff values were deter-
mined using the Youden index [20].
Univariate logistic regression models were fitted to
assess the association between treatment response and
baseline MRP8/14 levels. Linear regression was used to
evaluate the relationship between change in JADAS-10
disease activity and baseline MRP8/14 serum levels.
Change in JADAS-10 was defined as the difference be-
tween baseline and follow-up JADAS-10. Multivariable
linear models were fitted for change in JADAS-10 to
correct for other possible predictor variables and to assess
the additional value of MRP8/14 in predicting clinical re-
sponse. These variables were specified beforehand based
on preexisting knowledge of their relationship with serum
levels of MRP8/14 and/or the response to treatment (age
at onset of JIA, baseline JADAS-10, number of previously
used DMARDs, gender, baseline CHAQ score, ESR, dis-
ease duration) [4, 5, 21]. Missing data were handled using
the chained equations multiple imputation command ice
in Stata. Ten imputed datasets were created. Patients on
adalimumab or etanercept were compared, and were im-
puted together due to having identical characteristics. Of
the baseline JIA core set variable data (including VAS
pain, evaluated by patient/parent) 3.6 % were missing
(median of 0 missing values per patient (range 0–3). At
the last available follow up within 6 months of treatment
9.3 % of the JIA core set variable data were missing
(including VAS pain, median of 0 missing values per
patient (range 0–7)). Analyses were performed with IBM
SPSS Statistics for Windows Version 21.0, Stata/SE ver-
sion 13.0 and Prism (v5, GraphPad Software, La Jolla Cali-
fornia USA).
Results
Baseline characteristics
Baseline serum samples were available from 88 patients
with non-systemic JIA to measure MRP8/14 levels with
the in-house ELISA and of these 81 were available to
perform both in-house and commercial ELISA. Charac-
teristics of both the patients who started TNF inhibitors
and those who discontinued etanercept are summarized
in an additional table (see Additional file 1). Median
MRP8/14 (ng/ml) in patients who started TNF-inhibiting
treatment was 1,289 (IQR 795–2809). MRP8/14 serum
levels were significantly correlated to ESR at baseline
(Spearman’s rho 0.440, p <0.001). Presence of rheumatoid
factor, CHAQ at baseline, number of active joints and dis-
ease activity expressed as JADAS-10 were not correlated
with MRP8/14 levels.
Clinical response to treatment
A total of 25 % of patients (n = 22) did not achieve an
ACRpedi50 response or higher and were therefore con-
sidered non-responders to treatment. The remaining 66
patients were responders. Of these 66 patients, 46 achieved
ACRpedi70, and 31 patients reached a state of inactive dis-
ease. Mean JADAS-10 score at the last available follow up
within 6 months (median 3.2 months (IQR 2.6− 5.0)) was
5.7 (±5.4).
Baseline characteristics of responders and non-responders
are shown in Table 1. No significant differences were found
between responders and non-responders. Data on the use of
concomitant medication can be found in Additional file 1:
Table S1A. There were no significant differences be-
tween responders and non-responders in concomitant
medication such as systemic steroids (32 % of responders
vs 18 % of non-responders, p = 0.388) or DMARDs (91 %
of responders vs 73 % of non-responders, p = 0.064).
MRP8/14 serum levels and response to treatment
Baseline MRP8/14 serum levels were higher in responders
(median MRP8/14 of 1466 ng/ml (IQR 1045–3170))
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compared to non-responders (median MRP8/14 of
812 ng/ml (IQR 570–1178), p < 0.001) (Fig. 1). If we only
compare patients who achieved inactive disease with
those not achieving inactive disease, these differences
are also present: inactive disease vs no inactive disease:
median MRP 8/14 at start (ng/ml) 2287 (IQR 1053–
3672) vs 1174 (IQR 704–2030), p = 0.005.
On univariate logistic regression this resulted in an
odds ratio of 1.5 (95 % CI 1.1, 2.1) for achieving at least
an ACRpedi 50 response per 500 units of MRP (ng/ml).
Baseline MRP8/14 serum levels were significantly associ-
ated with change in JADAS-10 on linear regression ana-
lysis (β = 0.636 per 500 unit increase in ng/ml, 95 % CI
0.254, 1.018, p = 0.001).
Use of MRP8/14 as a prognostic marker for response to
treatment
Based on receiver operator characteristic (ROC) curve ana-
lysis, a cutoff value was identified for prediction of response
to treatment (ACR pedi50 or higher). Sensitivity, specificity
and likelihood ratios are given in Table 2.
Added value of MRP8/14 in prediction of response
We constructed a multivariable linear regression model
including known predictors (age at onset of JIA, baseline
JADAS-10, number of previously used DMARDs, gender,
baseline CHAQ score, ESR, disease duration) and subse-
quently added MRP8/14 to the model. In this multivari-
able model MRP8/14 was still significantly associated with
change in JADAS-10 (corrected β = 0.472 per 500 units
increase in ng/ml, 95 % CI 0.161, 0.782, p <0.001). The
only other variable significantly associated with change
in JADAS-10 was baseline JADAS-10 (corrected β = 0.678,
95 % CI 0.434, 0.921, p <0.001). The variables in the model
without MRP8/14 serum levels explained 50 % of the
variance in change in JADAS-10 within 6 months of treat-
ment (R2 = 0.50). Adding MRP8/14 to this model resulted
in a slightly better predictive model, with an R2 value
of 0.54 (p = 0.004).
Change in MRP8/14 levels after treatment
A follow-up measurement within 5 months after starting
treatment was available for 43 patients; 14 of these were
categorized as being non-responders. Treatment with TNF
inhibitors significantly lowered MRP8/14 serum levels in
responders (p <0.001) (Fig. 2b), but not in non-responders
(Fig. 2a). Patients who achieved inactive disease had a
greater change in MRP than those who did not achieve in-
active disease (median change in MRP 8/14 (ng/ml) -1034
(IQR -2723 to -401) vs -486 (IQR -1084 to 209)). Change
in MRP was significantly correlated with change in
JADAS10 (Spearman’s rho: 0.421, p = 0.006). There were
no significant differences in change in MRP levels after
anti-TNF treatment between patients who were or were
not treated concomitantly with systemic steroids and/or
DMARDs.
Table 1 Differences in baseline characteristics between
responders and non-responders
Baseline characteristic Responders Non-responders
(n = 66) (n = 22)
Female gender, n (%) 48 (73) 18 (82)
Age at onset of JIA in years,
median (IQR)
10.0 (4.2–12.3) 9.4 (3.5–13.7)
Disease duration in years,
median (IQR)
2.4 (1.1–4.9) 2.3 (0.8–7.7)
JADAS-10, median (IQR) 20 (14–21) 17 (11–22)
CHAQ score, median (IQR) 1.5 (0.7–2.2) 1.3 (0.6-2.0)
Number of active joints,
median (IQR)
11 (5–18) 8 (2–16)
ESR in mm/h, median (IQR) 16 (9–28) 12 (7–18)
Number of previously used
DMARDs, median (IQR)
1 (1–2) 1 (1–2)
JIA juvenile idiopathic arthritis, JADAS juvenile arthritis disease activity score,
IQR interquartile range, ESR erythrocyte sedimentation rate, CHAQ child health
assessment questionnaire, DMARDs disease modifying anti-rheumatic drugs
Fig. 1 Differences in myeloid related protein (MRP)8/14 serum levels
between non-responders and responders before starting treatment
Table 2 Sensitivity, specificity and likelihood ratios for the
determined cutoff value of myeloid related protein (MRP)8/14
to predict response to anti-TNF treatment
Accuracy measure
Cutoff level MRP8/14 (ng/ml) 1,193
Sensitivity 66 %
Specificity 81 %
Positive likelihood ratio 3.4
Negative likelihood ratio 0.4
Youden index 0.47
Area under the curve 0.76
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Association of MRP8/14 level and flare after etanercept
withdrawal after successful treatment
Patients who had flares within 6 months (n = 12) after
discontinuation of etanercept had higher MRP levels at
discontinuation than patients who did not have flares
(n = 14) (p = 0.031, median 1,025 ng/ml (IQR 588–1288)
vs 505 ng/ml (IQR 346–778) (Fig. 3)). Patients discontinu-
ing medication were allowed to have a PGA between 0
and 10 mm. Of the 26 patients discontinuing treatment,
14 patients had a PGA >0 (median PGA of 3). MRP levels
were comparable between the patients who had a PGA of
0 and patients who had a PGA >0 at discontinuation of
treatment (p = 0.432). Full disease activity parameters for
all patients at discontinuation can be found in Additional
file 1, Table S2.
The cutoff value for prediction of a flare after etanercept
withdrawal and the prognostic accuracy are reported in
Table 3.
Validation for routine use by commercial ELISA
Commercial MRP8/14 ELISA is available but is not vali-
dated for use as a monitoring tool for anti-TNF therapy.
Therefore, we aimed to validate our findings with the
commercial Bühlmann MRP8/14 Calprotectin ELISA to
make MRP8/14 as a marker for anti-TNF therapy widely
available. Measurements using the in-house ELISA cor-
related very well with those from the Bühlmann ELISA
(Pearson’s rho 0.902, p <0.001). Although MRP8/14 levels
appeared to be 3-fold to 4-fold higher when they were
measured with the Bühlmann ELISA, the associations be-
tween MRP8/14 and response, on both the achievement
of ACRpedi 50 or higher and on change in JADAS-10
were comparable. For predicting response to anti-TNF
treatment and flares after discontinuation in clinical re-
mission, the in-house ELISA and the Bühlmann ELISA
had the same accuracy. Full results for the Bühlmann
ELISA data are shown in Additional file 2.
Fig. 2 a Change in myeloid related protein (MRP)8/14 serum levels
in non-responders pre-treatment compared to levels after treatment
for an average of 3.2 months. b Change in MRP8/14 serum levels in
responders pre-treatment compared to levels after treatment for an
average of 3.2 months
Fig. 3 Differences in myeloid related protein (MRP)8/14 at time of
medication discontinuation between patients who then had persistent
remission and patients who had flares
Table 3 Sensitivity, specificity and likelihood ratios for the
determined cutoff value of myeloid related protein (MRP)8/14
predicting a flare within 6 months
Accuracy measure
Cutoff level MRP8/14 (ng/ml) 720
Sensitivity 75 %
Specificity 79 %
Positive likelihood ratio 3.5
Negative likelihood ratio 0.5
Youden index 0.54
Area under the curve (95 % CI) 0.75 (0.55, 0.95)
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Discussion
In this study we show that MRP8/14 can predict response
to anti-TNF treatment, although it has little additive value
to other clinical factors. Patients who responded to anti-
TNF treatment had higher levels of MRP8/14 at the start
of that treatment than patients who did not respond.
Disease activity declined more in patients with higher
levels of MRP8/14. In responders, these levels decreased
after initiation of treatment, and in non-responders
MRP8/14 levels were constant. When the disease had
become inactive and treatment with etanercept could
be stopped, MRP8/14 levels appeared to be higher for
patients in whom the disease flared than in patients
who did not experience a flare. The prognostic accur-
acies of the in-house ELISA and the Bühlmann ELISA
were comparable, although the cutoff levels were
different.
In recent years, MRP8/14 has been widely studied as
potential predictor of disease activity and response to
treatment in rheumatic and other inflammatory diseases.
In rheumatoid arthritis (RA), MRP8/14 has been used as
a predictor for response to biologic treatment [22]. In
JIA in particular, MRP8/14 levels are highly predictive of
disease activity and of disease flares in systemic JIA [11].
Also in enthesitis-related arthritis there is a relationship
between MRP8/14 levels and disease activity [23]. In a
more heterogeneous group of JIA patients, MRP8/14
levels have been shown to predict response to MTX treat-
ment [12]. The univariate odds ratio for achieving an
ACRpedi50 response or higher following MTX treatment
[12] is comparable to the odds ratio found in the present
study following anti-TNF treatment. Using the same
ELISA to measure MRP8/14 levels, the average serum
levels of MRP8/14 in that study were higher than in
our patients. Patients in the present study mostly had
MRP8/14 levels comparable to patients who did not re-
spond to MTX treatment [12]. This is not surprising as
failure of MTX treatment is an eligibility criterion for
treatment with biologic agents. Therefore there may be
a possibility of using MRP8/14 levels to decide which pa-
tient is more likely to respond to MTX and which patient
may be better off with biologic treatment right away. Un-
fortunately we did not have MRP8/14 serum levels for our
patients at the start of MTX treatment.
There are well-established experimental ELISA proto-
cols for MRP8/14, however, these are not available for
use in routine laboratories. The commercially available
Bühlmann ELISA kit has already been demonstrated to
perform well in analyzing patient serum samples. To ob-
tain reliable results in the range of MRP8/14 concentra-
tions found at different levels of disease activity in JIA,
serial dilution of individual sera to obtain reliable results
is necessary [24]. In addition, the level of MRP8/14
concentrations analyzed with the two assays varied
substantially. Therefore, a direct comparison of results
obtained with one ELISA with a result from a different
assay should not be made. Both methods were equally
accurate in predicting response to treatment and flares
after discontinuation in clinical remission.
For a biomarker to be used in informing therapeutic
choice, it will have to fulfill certain requirements. It has
to able to predict a certain outcome and the predictive
value has to be validated. It has to have additional value
on top of other known predictors. Additionally the pre-
diction should have therapeutic consequences. MRP8/14
has been shown to be associated with response to treat-
ment both in this and previous studies in JIA on both
relative (ACRpedi50) and absolute measures (change in
JADAS-10). Here, MRP8/14 added to the prediction of
change in disease activity, though its additive value was
small. Some of the responders and non-responders to
treatment had comparable MRP8/14 serum levels, and
sensitivity and specificity were not optimal for any cutoff
value, which is in line with the study by Moncrieffe et al.
[12]. Because prediction is not perfect, therapeutic deci-
sions cannot only be based on MRP8/14 levels. However,
it is unlikely that a single biomarker will ever be able to
perfectly predict response in the heterogeneous pool of
JIA patients. This biomarker has the advantage that it is
a relatively stable protein and easily measurable in serum,
in contrast to, for instance, cytokines such as TNF or
IL-1beta. Therefore, MRP8/14 could play a supporting
role in response prediction models for response to treat-
ment including clinical as well as laboratory measures,
which are under investigation for both JIA and RA
[4, 25–29]. More importantly, MRP8/14 might be used
to objectively monitor disease activity as it reflects
treatment response and confirms disease activity inde-
pendently from clinical parameters, and might be use-
ful as an early marker of response in clinical trials. In
the future, additional parameters are needed that could
contribute to a diagnostic panel to guide treatment deci-
sions. MRP expression could enable identification of
further biomarkers by defining and dissecting treatment
response groups.
For prediction of flares after discontinuation of treatment,
MRP8/14 can possibly be used as a prediction tool. MRP8/
14 serum levels have already been shown to be predictive
of flares after the discontinuation of MTX in JIA patients
[10]. We show that this is true to the same extent after
stopping etanercept in patients with non-systemic JIA after
inactive disease has been achieved. Additionally, we found
cutoff values comparable to the earlier specified cutoff
value for the in-house ELISA [10, 24]. Still, the cutoff values
did not perfectly predict flare or persistent remission after
discontinuation. For clinical practice this means that
we have to keep searching for additional features that
will provide a better prediction model.
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Conclusions
In conclusion, serum levels of MRP8/14 are associated
with response to treatment with etanercept in patients
with non-systemic JIA. MRP8/14 serum levels decrease
together with disease activity in responders to etanercept,
however, it is of minor predictive value when added to a
prediction model with known predictors. MRP8/14 serum
levels may be useful in practice to predict flares in patients
in clinical remission after cessation of etanercept. They
can also be determined using a commercially available
ELISA kit.
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